Broadcom
AVGO
Salesforce
CRM
Micron Technology
MU
4
Qualcomm
QCOM
5
Oracle
ORCL
US Stock MarketDetailed Quotes
XBIT XBiotech
- 3.010
- -0.150-4.75%
Trading Apr 24 11:47 ET
91.77MMarket Cap-2.39P/E (TTM)
3.140High3.000Low26.48KVolume3.140Open3.160Pre Close81.15KTurnover0.13%Turnover RatioLossP/E (Static)30.49MShares9.45052wk High0.50P/B59.71MFloat Cap2.65052wk Low--Dividend TTM19.84MShs Float28.004Historical High--Div YieldTTM4.43%Amplitude1.835Historical Low3.064Avg Price1Lot Size
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trade war escalates: What’s next for Chinese stocks?
🎙️Discussion 1. China-EU EV negotiations kick off recently. How do you think the negotiations will impact the performance of related stocks
Moo Earnings
Feb 17 19:21
Alibaba Q4 FY2024 Earnings Preview: Predict & Win Big! 🚀
XBiotech Stock Forum
XBiotech (NASDAQ: XBIT) recently announced promising data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Named 1-BETTER, this study focused on evaluating Natrunix, an anti-interleukin-1alpha antibody, in combination with a well-established chemotherapy regimen comp...
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
XBiotech (NASDAQ: XBIT) announced promising results from its Phase 1/2 trial for advanced pancreatic cancer treatment using Natrunix in combination with a standard chemotherapy regimen. The study, titled 1-BETTER, enrolled 65 subjects who received either the Natrunix combination or a placebo. Key findings include a 28% reduction in signif...
Where can check this information?
If I have 10 share....
Where is the money? 🧐
No comment yet